TATVANSETATVA CHIN PHARM CHEM LTDMediumNeutral
Announced Fri, 17 Jul · 16:03 IST

Q1 FY27 Investor Presentation: Revenue up 43% YoY, Margins Expand

Mgmt Guided Margin ImprovementInvestor Communications View source PDF

TATVA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+18.3%1-day move
₹1430.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+18.3+16.2+19.6+20.2+27.1
Up moveDown movePending
AI summary

Tatva Chintan filed its Q1 FY27 investor presentation. Revenue grew 43% YoY to Rs 1,671 Mn; PAT jumped 140% to Rs 160 Mn with PAT margin at 10% (vs 6%). EBITDA rose 86% YoY to Rs 323 Mn with margins expanding to 19% from 15%. FY26 revenue was Rs 5,059 Mn (up 32%), PAT Rs 421 Mn (up 636%). The company highlighted its strong product portfolio across PTC, SDA, ESS and PASC categories.

Likely market impact

Strong quarter with sharp YoY growth across revenue, profits and margins; signals business momentum and operational leverage.